home / stock / exai / exai quote
Last: | $5.18 |
---|---|
Change Percent: | 0.0% |
Open: | $5.14 |
Close: | $5.18 |
High: | $5.21 |
Low: | $4.89 |
Volume: | 570,726 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.18 | $5.14 | $5.18 | $5.21 | $4.89 | 570,726 | 07-22-2024 |
$5.14 | $5.19 | $5.14 | $5.27 | $5.05 | 263,761 | 07-19-2024 |
$5.12 | $5.4 | $5.12 | $5.4068 | $5.05 | 706,493 | 07-18-2024 |
$5.4 | $5.37 | $5.4 | $5.6 | $5.31 | 481,993 | 07-17-2024 |
$5.42 | $5.43 | $5.42 | $5.5 | $5.31 | 777,519 | 07-16-2024 |
$5.4 | $5.8 | $5.4 | $5.85 | $5.26 | 589,042 | 07-15-2024 |
$5.69 | $5.7 | $5.69 | $5.85 | $5.57 | 555,183 | 07-12-2024 |
$5.56 | $5.84 | $5.56 | $5.898 | $5.33 | 673,434 | 07-11-2024 |
$5.73 | $6.1 | $5.73 | $6.19 | $5.65 | 599,281 | 07-10-2024 |
$5.82 | $5.87 | $5.82 | $6.07 | $5.74 | 824,454 | 07-09-2024 |
$5.71 | $5.95 | $5.71 | $5.95 | $5.57 | 572,129 | 07-08-2024 |
$5.75 | $5.5 | $5.75 | $5.75 | $5.4 | 485,039 | 07-05-2024 |
$5.37 | $5.12 | $5.37 | $5.5 | $5.12 | 248,599 | 07-04-2024 |
$5.37 | $5.12 | $5.37 | $5.5 | $5.12 | 248,599 | 07-03-2024 |
$5.1 | $5.13 | $5.1 | $5.18 | $5.01 | 302,826 | 07-02-2024 |
$5.15 | $5.15 | $5.15 | $5.29 | $5.01 | 320,895 | 07-01-2024 |
$5.1 | $5.2 | $5.1 | $5.24 | $5.04 | 321,853 | 06-28-2024 |
$5.22 | $5.23 | $5.22 | $5.35 | $5.14 | 257,052 | 06-27-2024 |
$5.3 | $5.23 | $5.3 | $5.4 | $5.2 | 258,190 | 06-26-2024 |
$5.29 | $5.22 | $5.29 | $5.38 | $5.2 | 251,970 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...